Russia has completed the second phase of clinical trials for a Covid-19 vaccine based on the influenza virus, and researchers are compiling a results report for submission to regulatory authorities. The update came from officials at the Flu Research Institute, reflecting on the progress of this vector vaccine project and the ongoing review process. AA Smorodintseva Dmitry Lioznov from the Ministry of Health of Russia provided the update, noting that the study is progressing through its planned stages.
According to the official, the second phase focused on safety and immunogenicity, the vaccine’s ability to provoke an immune response in participants. With the data gathered, analysts are now evaluating the outcomes to determine the next steps in審 the regulatory pathway. The preliminary assessment indicates a favorable safety profile and a measurable immune response among participants, setting the stage for a broader effectiveness evaluation in the upcoming phase three trial.
As explained by the expert, determining effectiveness requires testing in a larger population during the third stage. That phase aims to confirm how well the vaccine protects against infection in real-world conditions and to quantify the level of protection achieved across diverse groups. The ongoing analysis will shape considerations for larger-scale trials and potential deployment timelines.
Officials highlighted that the vaccine design envisions updating the influenza-based component each year. This adaptation would help maintain protection against both Covid-19 and seasonal flu, addressing evolving viral strains. The development approach relies on the coronavirus N-protein to stimulate an immune response, a mechanism chosen to broaden immune recognition and durability of protection.
The report also points to broader topics in Russia’s vaccination landscape, including comparisons among flu vaccines and ongoing efforts to tackle other respiratory pathogens. The conversation about new vaccines reflects a continued focus on strengthening public health tools for seasonal and pandemic threats, with ongoing assessments and transparent reporting as the work advances.
Earlier, Russia announced progress in another vaccine effort, developing a nasal vaccine targeting a dangerous respiratory syncytial virus. This milestone underscores the country’s broader commitment to expanding respiratory disease prevention through diverse vaccine platforms and delivery methods, with research and regulatory steps guiding eventual use in the population. – End of report